Pulmonary Drug Delivery for Acute Respiratory Distress Syndrome

Overview

Journal Pulm Pharmacol Ther

Specialty Pulmonary Medicine

Date 2023 Jan 22

PMID 36682407

Authors

Qinqin Fei

Ian Bentley

Samir N Ghadiali

Joshua A Englert

Affiliations

Soon will be listed here.

Abstract

The acute respiratory distress syndrome (ARDS) is a life-threatening condition that causes respiratory failure. Despite numerous clinical trials, there are no molecularly targeted pharmacologic therapies to prevent or treat ARDS. Drug delivery during ARDS is challenging due to the heterogenous nature of lung injury and occlusion of lung units by edema fluid and inflammation. Pulmonary drug delivery during ARDS offers several potential advantages including limiting the off-target and off-organ effects and directly targeting the damaged and inflamed lung regions. In this review we summarize recent ARDS clinical trials using both systemic and pulmonary drug delivery. We then discuss the advantages of pulmonary drug delivery and potential challenges to its implementation. Finally, we discuss the use of nanoparticle drug delivery and surfactant-based drug carriers as potential strategies for delivering therapeutics to the injured lung in ARDS.

Citing Articles

The potential role of nanobodies in asthma therapy.

Khalid Salah Al-Sheakly B, Saheb Sharif-Askari F, Sharif-Askari N, Hundt J, Halwani R Front Pharmacol. 2025; 15:1510806.

PMID: 39902079 PMC: 11788342. DOI: 10.3389/fphar.2024.1510806.

Ferulic Acid: A Comprehensive Review.

Purushothaman J, Rizwanullah M Cureus. 2024; 16(8):e68063.

PMID: 39347187 PMC: 11438535. DOI: 10.7759/cureus.68063.

A novel extracellular vesicle paradigm for the treatment of COVID-19 induced acute respiratory distress syndrome (ARDS).

Osborn E, Ransom J, Shulman A, Sengupta V, Choudhry M, Hafiz A Respir Med Case Rep. 2024; 51:102087.

PMID: 39099663 PMC: 11295994. DOI: 10.1016/j.rmcr.2024.102087.

Comparative Efficacy of Inhaled and Intravenous Corticosteroids in Managing COVID-19-Related Acute Respiratory Distress Syndrome.

Abdelkader A, Alsfouk B, Saleh A, Abdelrahim M, Saeed H Pharmaceutics. 2024; 16(7).

PMID: 39065649 PMC: 11279829. DOI: 10.3390/pharmaceutics16070952.

Spray-Dried Nanolipid Powders for Pulmonary Drug Delivery: A Comprehensive Mini Review.

Abu Elella M, Khatib A, Al-Obaidi H Pharmaceutics. 2024; 16(5).

PMID: 38794342 PMC: 11125033. DOI: 10.3390/pharmaceutics16050680.

References

Dani C, Corsini I, Burchielli S, Cangiamila V, Romagnoli R, Jayonta B . Natural surfactant combined with beclomethasone decreases lung inflammation in the preterm lamb. Respiration. 2011; 82(4):369-76. DOI: 10.1159/000328928. View

Sharma A, Sharma S, Khuller G . Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother. 2004; 54(4):761-6. DOI: 10.1093/jac/dkh411. View

Nassimi M, Schleh C, Lauenstein H, Hussein R, Hoymann H, Koch W . A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur J Pharm Biopharm. 2010; 75(2):107-16. DOI: 10.1016/j.ejpb.2010.02.014. View

Matthay M, McAuley D, Ware L . Clinical trials in acute respiratory distress syndrome: challenges and opportunities. Lancet Respir Med. 2017; 5(6):524-534. DOI: 10.1016/S2213-2600(17)30188-1. View

Sinha P, Bos L . Pathophysiology of the Acute Respiratory Distress Syndrome: Insights from Clinical Studies. Crit Care Clin. 2021; 37(4):795-815. PMC: 8149201. DOI: 10.1016/j.ccc.2021.05.005. View

Taylor R, Zimmerman J, Dellinger R, Straube R, Criner G, Davis Jr K . Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA. 2004; 291(13):1603-9. DOI: 10.1001/jama.291.13.1603. View

Anderson P . Use of Respimat Soft Mist inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2007; 1(3):251-9. PMC: 2707154. DOI: 10.2147/copd.2006.1.3.251. View

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

Imai Y, Kuba K, Neely G, Yaghubian-Malhami R, Perkmann T, van Loo G . Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008; 133(2):235-49. PMC: 7112336. DOI: 10.1016/j.cell.2008.02.043. View

10.

Wang J, Hanafy M, Xu H, Leal J, Zhai Y, Ghosh D . Aerosolizable siRNA-encapsulated solid lipid nanoparticles prepared by thin-film freeze-drying for potential pulmonary delivery. Int J Pharm. 2021; 596:120215. DOI: 10.1016/j.ijpharm.2021.120215. View

11.

Altintas N, Atilla P, Iskit A, Topeli A . Long-term simvastatin attenuates lung injury and oxidative stress in murine acute lung injury models induced by oleic Acid and endotoxin. Respir Care. 2011; 56(8):1156-63. DOI: 10.4187/respcare.00770. View

12.

Rose F, Hattar K, Gakisch S, Grimminger F, Olschewski H, Seeger W . Increased neutrophil mediator release in patients with pulmonary hypertension--suppression by inhaled iloprost. Thromb Haemost. 2003; 90(6):1141-9. DOI: 10.1160/TH03-03-0173. View

13.

Chandel A, Goyal A, Ghosh G, Rath G . Recent advances in aerosolised drug delivery. Biomed Pharmacother. 2019; 112:108601. DOI: 10.1016/j.biopha.2019.108601. View

14.

Higuita-Castro N, Shukla V, Mihai C, Ghadiali S . Simvastatin Treatment Modulates Mechanically-Induced Injury and Inflammation in Respiratory Epithelial Cells. Ann Biomed Eng. 2016; 44(12):3632-3644. PMC: 5114146. DOI: 10.1007/s10439-016-1693-4. View

15.

Lavorini F, Fontana G . Targeting drugs to the airways: The role of spacer devices. Expert Opin Drug Deliv. 2009; 6(1):91-102. DOI: 10.1517/17425240802637862. View

16.

Grimaldi D, Durand A, Gleeson J, Taccone F . Failure of statins in ARDS: the quest for the Holy Grail continues. Minerva Anestesiol. 2016; 82(11):1230-1234. View

17.

Paranjpe M, Neuhaus V, Finke J, Richter C, Gothsch T, Kwade A . In vitro and ex vivo toxicological testing of sildenafil-loaded solid lipid nanoparticles. Inhal Toxicol. 2013; 25(9):536-43. DOI: 10.3109/08958378.2013.810315. View

18.

Namsirikul P, Chaisupamongkollarp S, Chantadisai N, BAMBERG P . Comparison of inhaled budesonide with oral prednisolone at two dose-levels commonly used for the treatment of moderate asthma. Eur Respir J. 1989; 2(4):317-24. View

19.

Ramakrishnan S, Nicolau Jr D, Langford B, Mahdi M, Jeffers H, Mwasuku C . Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021; 9(7):763-772. PMC: 8040526. DOI: 10.1016/S2213-2600(21)00160-0. View

20.

Sinha P, Delucchi K, McAuley D, OKane C, Matthay M, Calfee C . Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. Lancet Respir Med. 2020; 8(3):247-257. PMC: 7543720. DOI: 10.1016/S2213-2600(19)30369-8. View